China’s Ministry of Commerce announced it will lift the export ban on Illumina sequencing systems on November 10, reversing restrictions imposed earlier this year and reopening a critical market for the U.S. sequencing leader. Illumina confirmed the policy change while noting it remains on some Chinese trade lists. The reinstatement clears a major commercial obstacle and could accelerate instrument placements and reagent sales in China, a key global genomics market. Industry observers caution that lingering regulatory designations may still complicate certain transactions and long‑term customer engagement. Companies with China presence and partners will monitor subsequent implementation and any residual export controls affecting components and software.